Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 5
1977 2
1978 2
1980 2
1981 3
1982 2
1983 2
1984 3
1985 3
1986 1
1987 1
1988 2
1989 1
1992 2
1996 1
1998 2
1999 2
2001 1
2002 2
2003 1
2004 1
2005 2
2009 3
2010 2
2011 2
2012 1
2013 1
2014 3
2017 1
2018 2
2020 3
2021 7
2022 2
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

67 results

Results by year

Filters applied: . Clear all
Page 1
Treatment of Mycobacterium abscessus Pulmonary Disease.
Griffith DE, Daley CL. Griffith DE, et al. Chest. 2022 Jan;161(1):64-75. doi: 10.1016/j.chest.2021.07.035. Epub 2021 Jul 24. Chest. 2022. PMID: 34314673 Review.
Macrolide resistance has such a profoundly negative impact on M abscessus treatment response that preserving macrolide susceptibility with adequate companion drugs for macrolides is among the highest treatment priorities. ...Recent guidelines suggest that treatment should …
Macrolide resistance has such a profoundly negative impact on M abscessus treatment response that preserving macrolide susceptibility …
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
Lan Z, Ahmad N, Baghaei P, Barkane L, Benedetti A, Brode SK, Brust JCM, Campbell JR, Chang VWL, Falzon D, Guglielmetti L, Isaakidis P, Kempker RR, Kipiani M, Kuksa L, Lange C, Laniado-Laborín R, Nahid P, Rodrigues D, Singla R, Udwadia ZF, Menzies D; Collaborative Group for the Meta-Analysis of Individual Patient Data in MDR-TB treatment 2017. Lan Z, et al. Lancet Respir Med. 2020 Apr;8(4):383-394. doi: 10.1016/S2213-2600(20)30047-3. Epub 2020 Mar 17. Lancet Respir Med. 2020. PMID: 32192585 Free PMC article.
BACKGROUND: Treatment of multidrug-resistant tuberculosis requires long-term therapy with a combination of multiple second-line drugs. These drugs are associated with numerous adverse events that can cause severe morbidity, such as deafness, and in some instances can lead …
BACKGROUND: Treatment of multidrug-resistant tuberculosis requires long-term therapy with a combination of multiple second-line drugs …
Antibiotic efficacy varies based on the infection model and treatment regimen for Pseudomonas aeruginosa.
Cigana C, Ranucci S, Rossi A, De Fino I, Melessike M, Bragonzi A. Cigana C, et al. Eur Respir J. 2020 Mar 5;55(3):1802456. doi: 10.1183/13993003.02456-2018. Print 2020 Mar. Eur Respir J. 2020. PMID: 31624114 Free PMC article.
Different administration routes (intranasal, aerosol or subcutaneous) and treatment schedules (soon or 7 days post-infection) were tested.In the acute infection model, aerosol and subcutaneous administration of TOB reduced the bacterial burden and inflammatory response, wh …
Different administration routes (intranasal, aerosol or subcutaneous) and treatment schedules (soon or 7 days post-infection) were tested.In …
Radiographic severity and treatment outcome of Mycobacterium abscessus complex pulmonary disease.
Park J, Yoon SH, Kim JY, Gu KM, Kwak N, Yim JJ. Park J, et al. Respir Med. 2021 Oct;187:106549. doi: 10.1016/j.rmed.2021.106549. Epub 2021 Aug 4. Respir Med. 2021. PMID: 34380092 Free article.
INTRODUCTION: The lack of reliable predictors for the treatment response complicates decisions to initiate treatment in patients with Mycobacterium abscessus complex pulmonary disease (MABC-PD). ...
INTRODUCTION: The lack of reliable predictors for the treatment response complicates decisions to initiate treatment in patients with …
Nontuberculous mycobacterial lung disease caused by Mycobacterium avium complex - disease burden, unmet needs, and advances in treatment developments.
van Ingen J, Obradovic M, Hassan M, Lesher B, Hart E, Chatterjee A, Daley CL. van Ingen J, et al. Expert Rev Respir Med. 2021 Nov;15(11):1387-1401. doi: 10.1080/17476348.2021.1987891. Epub 2021 Oct 18. Expert Rev Respir Med. 2021. PMID: 34612115 Review.
A summary of the 2020 NTM guidelines specifically for MAC-LD and an overview of novel treatment options, including amikacin liposome inhalation suspension (ALIS) as the first approved therapy for refractory MAC-LD, and investigational drugs in testing phase are provided. . …
A summary of the 2020 NTM guidelines specifically for MAC-LD and an overview of novel treatment options, including amikacin liposome inhalat …
Newborn hearing screening: tobramycin and vancomycin are not risk factors for hearing loss.
de Hoog M, van Zanten BA, Hop WC, Overbosch E, Weisglas-Kuperus N, van den Anker JN. de Hoog M, et al. J Pediatr. 2003 Jan;142(1):41-6. doi: 10.1067/mpd.2003.mpd037. J Pediatr. 2003. PMID: 12520253
OBJECTIVE: To investigate the chance of detecting hearing loss with neonatal hearing screening in relation to exposure to tobramycin and vancomycin. STUDY DESIGN: Automated auditory brainstem response (A-ABR) hearing screening was performed in all neonates with at least on …
OBJECTIVE: To investigate the chance of detecting hearing loss with neonatal hearing screening in relation to exposure to tobramycin and van …
Conservative treatment of prosthetic valve endocarditis due to Mycobacterium fortuitum.
Kunin M, Salamon F, Weinberger M, Genkin I, Sagie A, Tur-Kaspa R. Kunin M, et al. Eur J Clin Microbiol Infect Dis. 2002 Jul;21(7):539-41. doi: 10.1007/s10096-002-0763-8. Epub 2002 Jul 10. Eur J Clin Microbiol Infect Dis. 2002. PMID: 12172746 Review.
The patient was treated medically and had a favorable clinical response. This is only the second report of survival after Mycobacterium fortuitum-group endocarditis, and the first of survival without surgical intervention. The duration of treatment is not well defined for …
The patient was treated medically and had a favorable clinical response. This is only the second report of survival after Mycobacteri …
Loteprednol and tobramycin in combination: a review of their impact on current treatment regimens.
Comstock TL, Holland EJ. Comstock TL, et al. Expert Opin Pharmacother. 2010 Apr;11(5):843-52. doi: 10.1517/14656561003667532. Expert Opin Pharmacother. 2010. PMID: 20210687 Review.
Loteprednol etabonate (LE) is a unique C-20 ester corticosteroid designed to produce a predictable therapeutic effect with a low incidence of side effects. Zylet (LE/T) a combination of LE and tobramycin (T) is indicated for the treatment of steroid-responsive ocula …
Loteprednol etabonate (LE) is a unique C-20 ester corticosteroid designed to produce a predictable therapeutic effect with a low inci …
Treatment of Corynebacterium equi pneumonia of foals: a review.
Prescott JF, Sweeney CR. Prescott JF, et al. J Am Vet Med Assoc. 1985 Oct 1;187(7):725-8. J Am Vet Med Assoc. 1985. PMID: 3902754 Review.
A third choice is sodium benzyl penicillin IV with gentamicin IM (2.2 mg/kg, TID) or with kanamycin IM (10 mg/kg, QID). Gentamicin should be combined with penicillin G or ampicillin and not used for longer than one week without monitoring for nephrotoxicosis. ...Chloramphe …
A third choice is sodium benzyl penicillin IV with gentamicin IM (2.2 mg/kg, TID) or with kanamycin IM (10 mg/kg, QID). Gentamicin sh …
67 results